ESKAPE病原体中的抗生素异质性耐药:从实验室到临床
本文为叙述性综述,检索Pubmed和Google共836篇文献,聚焦ESKAPE病原体异质性耐药的检测、流行病学与临床影响。异质性耐药仅对异质性万古霉素中介金黄色葡萄球菌有明确定义,作者汇总了适用于其他菌种和抗生素的微生物学定义,并指出需用标准化方法进一步研究。
要点
- 异质性耐药仅对异质性万古霉素中介金黄色葡萄球菌有明确定义。
- 群体分析谱是检测异质性耐药的参考标准。
- 目前不推荐临床实验室常规筛查异质性耐药,治疗失败等特定情况应由参考实验室检测。
核心结论
- 目前不推荐临床实验室系统筛查异质性耐药,但应认识该现象,治疗失败等特定情况应由参考实验室检测。
- 需采用标准化方法的更多研究来加深对异质性耐药的理解并进一步评估其临床影响。
研究设计与样本
- 叙述性综述,在Pubmed和Google以异质性耐药(异质性或异质)和抗生素耐药为关键词检索,从836篇基于摘要选出的文献中讨论与ESKAPE病原体异质性耐药检测、流行病学和临床影响最相关者。
主要发现
- 异质性耐药仅对异质性万古霉素中介金黄色葡萄球菌有明确定义。
- 作者汇总了适用于临床背景下其他细菌种类和抗生素的更广泛微生物学定义。
- 强调了群体分析谱的关键技术要点,其为检测异质性耐药的参考标准。
- 多药耐药革兰阴性病原体中对多黏菌素、β-内酰胺类(碳青霉烯类、头孢地尔)、磷霉素、替加环素和氨基糖苷类的异质性耐药常有报道。
- 异质性耐药所致治疗失败见于病例报告或回顾性研究,迄今仅在异质性万古霉素中介金黄色葡萄球菌中经Meta分析证实。
关键数值与推荐
- 原文未报告具体数值标准。
临床怎么用
- 为治疗泛耐药细菌感染,文中还讨论了使用定制抗生素组合靶向耐药分离株中敏感亚群的选项。
- 目前不推荐临床实验室系统筛查异质性耐药。
- 治疗失败等特定情况应认识到异质性耐药现象并由参考实验室检测。
局限性
- 异质性耐药缺乏诊断实验室统一的微生物学定义。
- 对大多数细菌种类其临床影响仍不明确。
- 异质性耐药所致治疗失败仅来自病例报告或回顾性研究,迄今仅在异质性万古霉素中介金黄色葡萄球菌中经Meta分析证实。
- 需采用标准化方法的更多研究来加深理解并进一步评估临床影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heteroresistance refers to subpopulation-mediated differential antimicrobial susceptibility within a clonal bacterial population. Usually, it designates a resistant subpopulation identified within an isolate considered susceptible by classical antimicrobial susceptibility testing. Heteroresistance lacks a uniform microbiological definition for diagnostic laboratories, and its clinical impact remains unclear for most bacterial species. OBJECTIVES: This narrative review aims to provide a practical overview on the latest developments in the field of heteroresistance for both clinical microbiologists and physicians, with a particular focus on ESKAPE pathogens. SOURCES: A literature search was performed on Pubmed and Google with the key words heteroresistance (heterogeneity OR heterogeneous) AND antibiotic resistance. Among the 836 publications selected based on their abstracts, the most relevant for the detection, epidemiology and clinical impact of heteroresistance in ESKAPE pathogens are discussed here. CONTENT: Heteroresistance is only clearly defined for heterogeneous vancomycin intermediate Staphylococcus aureus. We compiled a larger microbiological definition to be applicable to other bacterial species and antibiotics in the clinical context. We highlighted the key technical points of population analysis profile, which is the reference standard for detecting heteroresistance. Heteroresistance to polymyxins, β-lactams (carbapenems, cefiderocol), fosfomycin, tigecycline and aminoglycosides is frequently reported in multidrug-resistant gram-negative pathogens. Treatment failure due to heteroresistance has been described in case reports or retrospective studies, so far confirmed by meta-analyses in the case of heterogeneous vancomycin intermediate S. aureus only. Finally, to treat pandrug-resistant bacterial infections, the option of targeting susceptible subpopulations of resistant isolates using tailored antibiotic combinations is also discussed. IMPLICATIONS: Systematic heteroresistance screening by clinical laboratories is not currently recommended. Nevertheless, we should be aware of this phenomenon, and in specific cases, such as treatment failure, heteroresistance should be tested by reference laboratories. Additional studies using standardized methods are needed to improve our understanding of heteroresistance and further assess its clinical impact.
引用
- Roch M, Sierra R, Andrey DO, et al. Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside. Clin Microbiol Infect. 2022. PMID: 36270588. doi:10.1016/j.cmi.2022.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。